新辅助化疗在局部晚期食管癌治疗中的应用  

The Application of Neo-adjuvant Chemotherapy in Patients with Locally Advanced Esophageal Carcinomas

作　　者：王昊[1] 王雪峰[1] 高建林[1] 陈永红[1] 于桂霞[2] 

机构地区：[1]包头市肿瘤医院胸外科,内蒙古包头014030 [2]内蒙古科技大学包头医学院基础学院,内蒙古包头014030

出　　处：《内蒙古医学杂志》2011年第5期549-551,共3页Inner Mongolia Medical Journal

摘　　要：目的:新辅助化疗对局部晚期(ⅡB、Ⅲ期)食管癌手术切除率及术后生存率的影响。方法:应用多西他赛联合顺铂行食管癌新辅助化疗患者24例,观察化疗的有效率和不良反应,并与同期行单纯手术患者38例对比,比较两组手术切除率,术后并发症情况及生存率。结果:新辅助化疗组总有效率ORR(CR+PR)40.9%,不良反应可以耐受。根治性手术切除率较对照组高,两组差异有统计学意义(P<0.05)。新辅助化疗组术后3年生存率及5年生存率较对照组高,两组差异有统计学意义(P<0.05)。结论:多西他赛联合顺铂对食管癌术前新辅助化疗有助于提高根治性手术切除率,不良反应能耐受,不增加手术并发症,可提高患者3年及5年生存率。Objective：To study the effect on the excision rate and the postoperative survival rate of esophageal carcinomas（stage ⅡB,Ⅲ） by neo-adjuvant chemotherapy.Methods：62 patients with esophageal carcinoma were enrolled.There were 24 cases in the test group received neo-adjuvant chemotherapy with Docetaxel and Cisplatin for 2 cycles and followed by surgery（22 of 24 patients）.There were 38 cases in the control group were treated with surgery alone.Results：The ORR rate of neo-adjuvant chemotherapy was 40.9%.The radical resection rates was higher than control group,and there was statically significant difference between the two groups（P0.05）.3 and 5-year survival rates of the test group was higher than that in the control group（P0.05）.Conclusion：The neo-adjuvant chemotherapy with Docetaxel and Cisplatin for esophageal carcinoma could improve radical resection rate and 3 and 5-year survival rates,with tolerable side effect and less complication.

关 键 词：食管肿瘤 新辅助化疗 外科手术 

分 类 号：R734.2[医药卫生—肿瘤]